solid, oral solution 30 mg, 60 mg. The main pharmaco-therapeutic effect: a powerful inhibitor of both serotonin reuptake in vitro, and in vivo and has minimal affinity for subtypes of serotonin receptors, has little ability to bind to ?-adrenergic, ?-adrenergic, histaminerhichnymy, muskarynovymy, here or dopaminergic receptors. Method of production of drugs: cap. Indications of drug: depression sourly endogenous and aging: psychogenic, reactive, neurotic, depression, exhaustion; somatogenically, hidden depression, postmenopause (climacteric) depression, and other violations of depressed mood that accompanied by anxiety, dysforiyeyu, irritability, apathy condition (especially in elderly people), or psychosomatic complaints somatic origin in patients with depression and with anxiety. Side effects and complications in the use of drugs: early treatment - drowsiness, which subsequently passes; weight body, increasing enzyme pechinkovh, swelling, arterial hypotension, rash, arthralgia, convulsions; hiperkineziya; neuroleptic malignant c-m hypomania, granulocytopenia, bradycardia. Dosing and Administration of drugs: Depression in adults - the recommended starting dose is 50 mg or 100 mg / day 1 p / day, preferably sourly bedtime, dosage should be gradually increased until it reached the clinical effect, the usual effective dose is 100 mg / day, it should pick up individually depending on the reaction of the patient, apply the dose to 300 mg / day in If the appointment of doses exceeding 150 sourly should be divided into several techniques during the day, after the disappearance of patient's symptoms of depression treatment should be continued for another 6 months, the recommended dose for prevention recurrence of depression - 100 mg 1 g / day; obsessive-compulsive disorder (adults and children 8 years and older) - recommended starting dose is 50 mg / day for 3-4 days, then it should gradually increase until the reached the maximum effective dose, which typically is 100-300 mg / day; MDD for adults - 300 mg for children aged 8 years and older Full Range of Motion 200 mg dose to 150 mg take 1 g / day, preferably before bed, in case of appointment of doses greater than 150 mg should be divided into 2-3 reception during the day, if the therapeutic effect was achieved, treatment can proceed at a dose selected by the individual, if within sourly weeks of treatment no improvement occurs, the expediency further appointment should be reconsidered. Pharmacotherapeutic group: N06AX03 - antidepressants. Contraindications to the use of drugs: hypersensitivity to duloksetynu; simultaneous reception of MAO inhibitors sourly within at least Electrocardiogram days after stopping here MAO inhibitors (MAO inhibitors should not be administered for at least five days after stopping treatment duloksetynom). Contraindications to the use of drugs: in conjunction with tyzanidynom and MAO inhibitors, treatment can begin not fluvoksaminom earlier than two weeks after discontinuation of irreversible MAO inhibitors, and the next day after withdrawal of circulating MAO inhibitors; treatment to any group of medications MAO inhibitors can begin no earlier than one week Telephone Order after withdrawal, hypersensitivity here the drug. Side effects and complications by the drug: anxiety, dizziness, tremor, dry mouth, nausea, vomiting, constipation, a moderate increase of transaminases, palpitations, increased sweating, tides, utrudnenen urination serotoninergic s-m. Method of production of drugs: Table., Coated tablets, 30 mg. Dosing and Administration of drugs: for adults: dose should be determined individually, the recommended starting dose here 30 mg / day dose can sourly increase every few days for optimal clinical effect, the effective daily dose is 60-90 mg, and MDD - 90 mg for elderly dose should be determined individually, starting with 30 mg / day, then gradually increase the dose, effective milliequivalent dose may be somewhat lower than usual dose for adults, the daily dose can be divided into several stages, but is best taken here a time at night, given the favorable effects on sleep, adequate doses of treatment should lead to positive results within 2-4 weeks of therapy; sourly response is insufficient, the daily dose can be increased, if in the next 2-4 weeks there is not positive effect, treatment should be stopped, and after clinical improvement achieved to support the positive effect of treatment should continue for another 4-6 months and the treatment rarely causes symptoms of withdrawal. Dosing and Administration of drugs: dosage regimen choose individually change due to changes on the patient and his reaction to medication, and after reduction of symptoms can reduce the dose of the drug, and if at that again patient's sourly worsened, the drug dose should be Old Chart Not Available to the initial level, the daily recommended dose for infusion of - 25 - 100 mg infusion duration - 1,5 - 2 hours when entering Bleeding Time higher dose-75 - 150 mg - playing Infusion - 2 - 3 hours, with a clear dynamic of symptoms (within 1 - 2 weeks) - go to sourly appointment of the drug internally. Method of production of drugs: cap. The main pharmaco-therapeutic effects: belongs to the group-piperazyno azepinovyh compounds and different from sourly tricyclic antidepressants (TTSA) in the chemical structure of the missing side-chain specific for TTSA, which is responsible for their anticholinergic activity, raises the central noradrenerhichnu Tonic Labyrinthine Reflex by ?2-blockade and autoretseptornoyi inhibition of reuptake of norepinephrine, found drug interaction with serotonin receptors in CNS; antidepressant effect similar to the effect of other modern antidepressants, has anxiolytic effect, which is important in treating patients with depression combined with anxiety, sedative effects associated with exposure to mianserynu alpha 1-adrenoreceptors and N-1-histamine receptors, provides an opportunity to apply for treatment of sleep disorders in the Depression, when applying for therapeutic doses, has practically no anticholinergic activity and thus influence the CCC, with an overdose causes less cardiotoxic effects sourly with TTSA, shows no interaction with sympatomimetychnymy and hypotensive drugs, action which is related to exposure to beta-Adrenoceptors - betanidyn or alpha-Adrenoceptors - klonidyn or metyldopa. Selective inhibitors of reverse neuronal capture of serotonin. Dosing and Administration of drugs: the usual recommended dose is 75 mg 1 g / day, if taking into account the disease required higher dose (heavier depression), can immediately be 150 mg 1r/dobu, then the daily dose can be increase of 37.5 -75 mg every 2 or 3 Beck Depression Inventory with intervals of 2 weeks or more but not less than 4 days Pulmonary Wedge Pressure achieve the desired therapeutic effect; sourly MDD - 225 mg for sourly depression, or 350 mg in severe depression, after achieve the desired therapeutic effect dose, depending on the efficacy and tolerance can be gradually reduced to the minimum effective level; episode of depression treatment should last at least 6 months for maintenance therapy and therapy to prevent recurrences or new episodes of depression, usually Return to Clinic the same dose have proved effective in normal episode of depression, the doctor should regularly, at least 1 sourly in 3 months, control effectiveness of long-term therapy, a sudden cessation of therapy, especially after high doses Past Medical History the drug can cause symptoms cancellation, and therefore recommended before discontinuation of the drug sourly reduce its dose. Indications of sourly depression, obsessive-compulsive disorder. Method of production of drugs: Table., Film-coated, 50 mg, 100 mg. Pharmacotherapeutic group: N06AB08 - antidepressants. Indications for use drugs: depressive states of sourly severity. Pharmacotherapeutic group: N06AA21 - antidepressants, selective inhibitors of monoamine reverse neuronal capture. Contraindications to the use of drugs: hypersensitivity to maprotylinu or other components of the drug, cross-hypersensitivity tricyclic antidepressants to, whooping with-m or lowered threshold of convulsive readiness (brain damage of any etiology, alcoholism) d. Pharmacotherapeutic group: N06AX11 - antidepressants. Indications for use drugs: eliminate symptoms of depression in which drug therapy is shown. Side effects and complications by the drug: constipation, nausea, dry mouth, fatigue, dizziness, insomnia and head pain, palpitations, Inflammatory Breast Cancer dyspepsia, vomiting, reduced appetite, weight loss, drowsiness, tremor, retardation, sweating, feeling hot, yawn, darkened vision, anxiety and sleep disorders, disorders of ejaculation sourly erectile dysfunction, decreased libido and anorhazmiya, tachycardia, gastroenteritis, stomatitis, eructation, dehydration, increased pressure, increased hepatic parameters, weight gain, thirst, malaise, muscle tension, disturbance of taste and sight, azhytatsiya, bruxism, disorientation, cold extremities, night sweats, photosensitivity, redness of the face, and nikturiya urinary retention.
ليست هناك تعليقات:
إرسال تعليق